Mucosal Vaccine Development Based on Liposome Technology. - Wikidata - awgldk - TriplyDB

Mucosal Vaccine Development Based on Liposome Technology.

Mucosal Vaccine Development Based on Liposome Technology.

http://www.wikidata.org/entity/Q37581129

about

Nanoparticle-allergen complexes for allergen immunotherapy.Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro.Modulating the immune system through nanotechnology.The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs

P2860

Q33834985-962CC7EF-01AD-4592-A4CB-4C125A8D5F2B Q40121454-96EC67DA-2AB3-46F0-8F19-55E6BE1A3D83 Q48630939-AF2758A9-D6FE-4F7A-B84E-8A6D273E4BC3 Q50124824-836B0B33-F9BA-4468-8AEA-FDDEF5AFA488 Q52725104-DB6B9153-8978-4427-BF1F-4D356609CBA1 Q57091953-061CB079-82B6-4FF1-9EED-C2601F2783E4 Q58698634-68E6E495-5AE4-4A3B-BBFE-2D36AABECB2A

P2860

Mucosal Vaccine Development Based on Liposome Technology.

http://www.wikidata.org/entity/Q37581129

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mucosal Vaccine Development Based on Liposome Technology.

@en

Mucosal Vaccine Development Based on Liposome Technology.

@nl

type

label

Mucosal Vaccine Development Based on Liposome Technology.

@en

Mucosal Vaccine Development Based on Liposome Technology.

@nl

prefLabel

Mucosal Vaccine Development Based on Liposome Technology.

@en

Mucosal Vaccine Development Based on Liposome Technology.

@nl

P1433

Q37581129-251CB123-75F1-4FE8-B793-205DD6BE0645

P1476

Q37581129-ECCBD28B-6B99-452B-89F7-D15155836C5B

P2093

Q37581129-077D8235-154F-4589-9251-648C865C89CA

Q37581129-E6BD9B59-6FFD-4018-8DF4-0BFFF10C3F06

P275

Q37581129-245000E2-7645-4C99-ACB4-30602E22FE43

P2860

Q37581129-022ED757-1105-49FC-8F0C-14A6F52B96C1

Q37581129-0AB23396-E9A6-4475-833F-4625F0540B2B

Q37581129-0BF7BAF0-7421-47BE-BF25-7636326EB73D

Q37581129-0D888BDA-447F-4D30-A52C-45B6E917EE62

Q37581129-12523791-02C2-4816-8ADE-C36EB810F398

Q37581129-142C1BDA-051B-473E-A21D-FEEBAD551877

Q37581129-1540307F-E115-428E-85D2-BAAFB8C5C865

Q37581129-18DBFBB1-AE92-4C86-912E-1BA63C5A93BD

Q37581129-1ACCDF44-8C5B-4255-AAAD-A916A484A9E8

Q37581129-1DE7AF06-1AB5-40FB-9F45-D69B0E25DDED

P304

Q37581129-D16B412D-3B9D-4361-8A34-645443DFDD00

P31

Q37581129-5337E9CB-B1D9-4E2A-8022-2C7F66B53BAB

Q37581129-CE433AF7-83EE-44E3-8C2A-385D53C811A1

P356

Q37581129-AB5EE29C-7BF6-4C2B-97AB-D7836EA08564

P478

Q37581129-E541D1A4-EF18-4DD0-8A04-C0770E2FBD7D

P50

Q37581129-2AA80751-8490-48B6-A508-47F2AD02DC0A

Q37581129-5B53EA28-1767-4650-9CE5-77955202948C

Q37581129-C2B4A65C-ADDD-4F39-A8B0-5A4359455ECF

P577

Q37581129-C921C5B6-F737-47CA-BBBC-C92C2C70C504

P698

Q37581129-B7E69CAE-5151-4FED-9549-B8190BE27EC5

P921

Q37581129-55B1509A-D8B0-4B97-B12F-BD1377F5283D

Q37581129-7B2EF12C-F06D-49FB-8A86-01A6CFEC3526

Q37581129-E4F917EA-4061-45B2-9AAD-98DA61394313

P932

Q37581129-4AC9BDEF-EA87-4832-AC8F-C72BE348B51B

P356

P1433

Journal of Immunology Research

P1476

Mucosal Vaccine Development Based on Liposome Technology.

@en

P2093

Fredrik Höök

http://www.w3.org/2001/XMLSchema#string

Karin Norling

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts

Protein-nanoparticle interactions

Toll-like receptors and innate immunity

Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits.

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.

Preparation of double liposomes and their efficiency as an oral vaccine carrier.

P304

5482087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/5482087

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P50

Valentina Bernasconi

P577

2016-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28127567

http://www.w3.org/2001/XMLSchema#string

P921

manufactured product

pharmaceutical preparation

biomedical investigative technique

P932

5227169

http://www.w3.org/2001/XMLSchema#string